Clinical Trial Update: Third-line Treatment of Gefitinib in NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating third-line gefitinib in non-small cell lung cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED